tiprankstipranks
Advertisement
Advertisement
Viking Therapeutics initiated with a Buy at Lake Street
PremiumThe FlyViking Therapeutics initiated with a Buy at Lake Street
25d ago
Viking Therapeutics assumed with a Buy at Truist
Premium
The Fly
Viking Therapeutics assumed with a Buy at Truist
26d ago
Viking Therapeutics Shareholders Back Board, Pay, and Auditor
Premium
Company Announcements
Viking Therapeutics Shareholders Back Board, Pay, and Auditor
27d ago
Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley
PremiumThe FlyViking Therapeutics price target lowered to $95 from $99 at Morgan Stanley
2M ago
Viking Therapeutics Maintained at Buy as VK2735 Advances Through Phase 3, Price Target Reaffirmed at $102
Premium
Ratings
Viking Therapeutics Maintained at Buy as VK2735 Advances Through Phase 3, Price Target Reaffirmed at $102
2M ago
Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)
Premium
The Fly
Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)
2M ago
Viking Therapeutics: Accelerated VK2735 Obesity Program and Single‑Molecule Strategy Support Buy Rating and Favorable Risk‑Reward
PremiumRatingsViking Therapeutics: Accelerated VK2735 Obesity Program and Single‑Molecule Strategy Support Buy Rating and Favorable Risk‑Reward
3M ago
Strong Enrollment and Phase 3 Momentum Underpin Buy Rating on Viking Therapeutics’ Obesity Program
Premium
Ratings
Strong Enrollment and Phase 3 Momentum Underpin Buy Rating on Viking Therapeutics’ Obesity Program
3M ago
Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735
Premium
The Fly
Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100